SCHEMBL23573287

SCHEMBL23573287

CC1CCC(NC(=O)O)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.59
RAB9A P51151 7/20 0.49
NPC1 O15118 5/20 0.49
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
MMP2 P08253 1/20 0.44
MMP8 P22894 1/20 0.44
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ADRA2A P08913 1/20 0.43
MAPK1 P28482 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
GFER P55789 1/20 0.42
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL245467 0.87
SCHEMBL6658887 0.87 EPHX2 (0.50) EPHX1RAB9ANPC1MMP2MMP8
SCHEMBL20214960 0.86 EPHX1 (0.45) EPHX1RAB9ANPC1TAS1R3TAS1R1
Hydrochloric Acid SCHEMBL11416981 0.84
SCHEMBL11047125 0.82 EPHX1 (0.83) EPHX1RAB9ANPC1TAS1R3TAS1R1
SCHEMBL3273214 0.80 POLB (0.41) EPHX1RAB9ANPC1TAS1R3TAS1R1
SCHEMBL15388389 0.80 POLB (0.41) EPHX1RAB9ANPC1TAS1R3TAS1R1
SCHEMBL852875 0.80 ATM (0.48) EPHX1RAB9ANPC1MMP2MMP8
SCHEMBL13036243 0.80 EPHX1 (0.59) EPHX1RAB9ANPC1TAS1R3TAS1R1
SCHEMBL4761484 0.80 EPHX1 (0.59) EPHX1RAB9ANPC1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348518-A1 HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-11-02 US disclosed
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2021-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ADORA2A, ENTPD1 EPHX1 629/4885RAB9A 2930/4885NPC1 1512/4885
US-20230348518-A1 HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS RECQL, DDX21, DDX41 EPHX1 1264/4885RAB9A 1832/4885NPC1 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.